Skip to main content
. 2020 Jun 5;20(2):1664–1674. doi: 10.3892/etm.2020.8847

Figure 2.

Figure 2

miR-140-3p enhances the sensitivity of LUAD cells to cisplatin. (A) Reverse transcription-quantitative PCR analysis of miR-140-3p expression in the A549 and Calu3 cell lines following transfection with the miR-140-3p mimic or the control mimic. (B) Colony formation of A549 and Calu3 cells following transfection with the miR-140-3p mimic or the control mimic and 5 µg/ml cisplatin treatment. Cell viability of (C) A549 and (D) Calu3 cells as determined by MTT assay, following transfection with the miR-140-3p mimic or the control mimic and then treatment with different concentrations of cisplatin. Caspase-3 activity of (E) A549 and (F) Calu3 cells was determined by caspase-3 assay, following transfection with the miR-140-3p mimic or the control mimic and then treatment with 5 µg/ml cisplatin. All experiments were performed in triplicate and data are presented as the mean ± standard deviation. *P<0.05 and **P<0.01 vs. control mimic. miR, microRNA; LUAD, lung adenocarcinoma.